Search results for " neprilysin"

showing 3 items of 3 documents

Lack of genetic association of neutral endopeptidase (NEP) with complex regional pain syndrome (CRPS)

2010

Complex regional pain syndrome (CRPS) is a condition that is characterized by severe pain and exaggerated neurogenic inflammation, which may develop after injury or surgery. Neurogenic inflammation is mediated by neuropeptides, such as calcitonin gene-related peptide (CGRP) and substance P (SP) that are released from nociceptors. Genetic factors may play a role in CRPS as was suggested by the occurrence of familial cases and several genetic association studies investigating mainly the human leukocyte antigen (HLA) system. Here we investigated the role of neutral endopeptidase (NEP), a key enzyme in neuropeptide catabolism. NEP dysfunction resulting in reduced inactivation of neuropeptides m…

AdultMalemedicine.medical_specialtyLinkage disequilibrium5' Flanking RegionSubstance PHuman leukocyte antigenBiologyCalcitonin gene-related peptideLinkage Disequilibriumchemistry.chemical_compoundInternal medicinemedicineHumansGenetic Predisposition to DiseaseDinucleotide RepeatsPromoter Regions GeneticNeprilysinGenetic Association StudiesGenetic associationNeurogenic inflammationPolymorphism GeneticGeneral NeurosciencefungiMiddle Agedmedicine.diseaseCRPS Pain NEP Association reflex sympathetic dystrophy syndrome type-i facilitated neurogenic inflammation nociceptive abnormalities alzheimers-disease neprilysin gene rat model enkephalinase prevalence dystoniaEndocrinologyComplex regional pain syndromechemistryCase-Control StudiesFemaleNeprilysinComplex Regional Pain Syndromes
researchProduct

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study

2020

Altres ajuts: This work was supported in part by Fundació La Marató de TV3 (201516-10, 201502-30), Societat Catalana de Cardiologia, "la Caixa" Banking Foundation. Altres ajuts: PERIS/SLT002-16-00234 Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor developed for the treatment of heart failure with reduced ejection fraction. Its benefits are achieved through the inhibition of neprilysin (NEP) and the specific blockade of the angiotensin receptor AT1. The many peptides metabolized by NEP suggest multifaceted potential consequences of its inhibition. We sought to evaluate the short-term changes in serum endorphin (EP) values and their relation with patients' p…

medicine.medical_specialtyAngiotensin receptorEndorphins; Heart failure; Neprilysin; Sacubitril/valsartan; α-Endorphin; γ-Endorphinα‐EndorphinVascular damage Radboud Institute for Health Sciences [Radboudumc 16]HemodynamicsPilot ProjectsHeart failure030204 cardiovascular system & hematologyγ‐EndorphinvalsartanSacubitril03 medical and health sciences0302 clinical medicineOriginal Research ArticlesInternal medicinemedicineHumansDiseases of the circulatory (Cardiovascular) systemalpha-EndorphinOriginal Research ArticleProspective Studies030212 general & internal medicineSacubitril/valsartanγ-EndorphinAngiotensin II receptor type 1Ejection fractionbusiness.industryα-EndorphinStroke Volumegamma-Endorphinmedicine.diseaseSacubitrilValsartanRC666-701Heart failureCardiologyNeprilysinEndorphinsCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drug
researchProduct